Vivanza Biosciences Ltd
Incorporated in 2016, Vivanza Biosciences Ltd is in the business of providing medicines and healthcare solutions[1]
- Market Cap ₹ 8.00 Cr.
- Current Price ₹ 2.00
- High / Low ₹ 2.94 / 1.90
- Stock P/E
- Book Value ₹ 1.15
- Dividend Yield 0.00 %
- ROCE -2.77 %
- ROE -15.6 %
- Face Value ₹ 1.00
Pros
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -5.02% over past five years.
- Promoter holding is low: 20.0%
- Company has a low return on equity of 3.85% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 398 days.
- Promoter holding has decreased over last 3 years: -27.8%
- Working capital days have increased from 82.8 days to 154 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 3 | 6 | 3 | 10 | 10 | 10 | 18 | 28 | 7 | 110 | |
| 0 | 4 | 6 | 3 | 10 | 10 | 10 | 17 | 27 | 8 | 110 | |
| Operating Profit | -0 | -0 | 1 | -0 | -0 | 0 | -0 | 1 | 1 | -0 | 0 |
| OPM % | -9% | 9% | -1% | -4% | 1% | -1% | 4% | 4% | -5% | 0% | |
| 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -0 | -0 | 0 | -0 | -0 | 0 | 0 | 1 | 1 | -1 | -0 |
| Tax % | 0% | 0% | 13% | 0% | 0% | 42% | 0% | 17% | 21% | 2% | |
| -0 | -0 | 0 | -0 | -0 | 0 | 0 | 1 | 1 | -1 | -0 | |
| EPS in Rs | -0.32 | -0.08 | 0.05 | -0.11 | -0.05 | 0.02 | 0.08 | 0.15 | 0.14 | -0.17 | -0.04 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -5% |
| 3 Years: | -11% |
| TTM: | 869% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -88% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -13% |
| 5 Years: | -32% |
| 3 Years: | -50% |
| 1 Year: | -17% |
| Return on Equity | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 5% |
| 3 Years: | 4% |
| Last Year: | -16% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.19 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Reserves | -0 | -0 | -0 | -1 | -1 | -1 | -1 | 0 | 1 | -0 | 1 |
| 0 | 1 | 1 | 1 | 0 | 0 | 6 | 8 | 5 | 9 | 10 | |
| 0 | 3 | 5 | 6 | 9 | 5 | 7 | 10 | 10 | 4 | 35 | |
| Total Liabilities | 1 | 7 | 10 | 11 | 12 | 8 | 16 | 22 | 20 | 16 | 50 |
| 0 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 | 5 | 8 | 9 | 10 | 6 | 13 | 20 | 17 | 14 | 47 | |
| Total Assets | 1 | 7 | 10 | 11 | 12 | 8 | 16 | 22 | 20 | 16 | 50 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0 | -2 | -0 | 1 | 3 | -3 | 2 | -1 | 2 | -2 | |
| 0 | 2 | 0 | 0 | 0 | -0 | 0 | 0 | -0 | -0 | |
| 0 | 0 | -1 | -1 | -3 | 3 | -2 | 1 | -2 | 2 | |
| Net Cash Flow | 0 | 0 | -1 | -0 | 0 | -0 | -0 | 0 | 0 | -0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 267 | 287 | 782 | 250 | 231 | 275 | 256 | 151 | 398 | |
| Inventory Days | 215 | 150 | 309 | 38 | 26 | 92 | 55 | 28 | 121 | |
| Days Payable | 304 | 319 | 878 | 319 | 154 | 207 | 211 | 116 | 140 | |
| Cash Conversion Cycle | 178 | 118 | 213 | -32 | 103 | 160 | 99 | 64 | 379 | |
| Working Capital Days | 332 | 237 | 469 | 109 | 104 | 103 | 50 | 44 | 154 | |
| ROCE % | -10% | 13% | -0% | 6% | 17% | 12% | 11% | 10% | -3% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Permanent Employees absolute ・Standalone data |
|
||||||||||
| Trade Receivables Turnover Ratio (Standalone) times ・Standalone data |
|||||||||||
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
13 Feb - Copy of newspaper advertisment published in English daily newspaper (Indian Express) and one daily newspaper (Financial Express) in Gujarati language of the region, where the …
-
Non-Applicability Of Statement Of Deviation Or Variation Under Regulation 32 Of SEBI (LODR) Regulations, 2015.
12 Feb - Confirms no public/rights/preferential issue proceeds; Reg 32 deviation statement not applicable.
- Outcome Of The Board Meeting And Submission Of Un-Audited Financial Results For The Quarter And Nine Months Ended 31ST December 2025 12 Feb
-
Board Meeting Outcome for Outcome Of The Board Meeting And Submission Of Un-Audited Financial Results For The Quarter And Nine Months Ended 31ST December 2025
12 Feb - Board approved standalone and consolidated unaudited results for quarter and nine months ended 31-Dec-2025 with limited review.
-
Board Meeting Intimation for Consideration Of Financial Result For The Quarter And Nine Months Ended 31St December, 2025
5 Feb - Board meeting on Feb 12, 2026 to approve unaudited Q3/9M results; trading window closed.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
VBL's core areas include research and development, manufacturing, and distribution of a wide range of pharmaceutical products